US$ 24.43
do glp 1 drugs cause muscle loss GLP-1 medications really major loss? Or have we been misunderstanding what DXA scans are measuring? π€ For years, the β40% muscle lossβ claim has been one of the biggest Glucagon-like peptide-1 receptor agonists and
Description
doi: 10.1038/mp.2016.3 68 HaapakoskiR.EbmeierK

Fitty Tip: Craving something sweet
If left untreated, it can lead to complications like blindness, kidney failure, heart attacks, stroke and lower limb amputation
Ashraf Adly El-Sheikh chairman of ADC center (Abou-Seifien Diabetes Center) in Egypt for his patience, motivation, enthusiasm and immense knowledge

Sitagliptin, anagliptin, gemigliptin, and teneligliptin form class 3 of the DPP-4 inhibitors (see Figure 2) ( Figure 2 The clinically most relevant and important action of DPP-4 inhibitors is the endogenous elevation of the incretin hormone concentration of GLP-1 that consecutively leads to a glucose-dependent stimulation of insulin secretion and an inhibition of glucagon secretion ( This article gives an overview on the characteristics of the various DPP-4 inhibitors in clinical use and highlights the positioning of the drug class in the guidelines for the treatment of type 2 diabetes

Youll walk away with a completely new toolkit for breaking through patient resistance, dissolving medication hesitancy, and creating clinical encounters that actually inspire change!
